Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source

Vaccine

Volumn 30, Issue 1, 2011, Pages 29-34

  Gill, C J ^a,c   Ram, S ^b   Welsch, J A ^a   De Tora, L ^a   Anemona, A ^d  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Bactericidal assay; Correlation; Human; Meningococcal vaccine; Rabbit; Serum

Indexed keywords

MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; COMPLEMENT; MENACWY CRM VACCINE; MENACWY-CRM VACCINE;

ADOLESCENT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; HUMAN; MALE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SERUM BACTERICIDAL ACTIVITY; ANIMAL; CHILD; COMPARATIVE STUDY; EVALUATION; FEMALE; IMMUNOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); RABBIT; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADOLESCENT; ANIMALS; BLOOD BACTERICIDAL ACTIVITY; CHILD; CLINICAL TRIALS, PHASE II AS TOPIC; COMPLEMENT SYSTEM PROTEINS; FEMALE; HUMANS; MALE; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP A; NEISSERIA MENINGITIDIS, SEROGROUP C; NEISSERIA MENINGITIDIS, SEROGROUP W-135; NEISSERIA MENINGITIDIS, SEROGROUP Y; RABBITS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84858607334     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.10.068     Document Type: Article

References (29)

1. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009;27(June (Suppl. 2)):B112-6.
2. Flexner S. The results of the serum treatment in thirteen hundred cases of epidemic meningitis. J Exp Med 1913;17(5):553-76.
3. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969;129(June (6)):1307-26.
4. Hellerud BC, Aase A, Herstad TK, Naess LM, Kristiansen LH, Troseid AM, et al. Critical roles of complement and antibodies in host defense mechanisms against Neisseria meningitidis as revealed by human complement genetic deficiencies. Infect Immun 2010;78(February (2)):802-9.
5. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 1969;129(June (6)):1327-48.
6. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003;10(September (5)):780-6.
7. Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J 2009;28(February (2)):86-91.
8. Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008;299(January (2)):173-84.
9. Borrow R, Goldblatt D, Finn A, Southern J, Ashton L, Andrews N, et al. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom. Infect Immun 2003;71(October (10)):5549-55.
10. Santos GF, Deck RR, Donnelly J, Blackwelder W, Granoff DM. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol 2001;8(May (3)):616-23.
11. Findlow H, Plikaytis BD, Aase A, Bash MC, Chadha H, Elie C, et al. Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults. Clin Vaccine Immunol 2009;16(July (7)):969-77.
12. Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 2001;69(March (3)):1568-73.
13. Artenstein MS, Gold R, Zimmerly JG, Wyle FA, Schneider H, Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med 1970;282(February (8)):417-20.
14. Reingold AL, Broome CV, Hightower AW, Ajello GW, Bolan GA, Adamsbaum C, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985;2(July (8447)):114-8.
15. Fairley CK, Begg N, Borrow R, Fox AJ, Jones DM, Cartwright K. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J Infect Dis 1996;174(December (6)): 1360-3.
16. Welsch JA, Granoff D. Immunity to Neisseria meningitidis group B in adults despite lack of serum bactericidal antibody. Clin Vaccine Immunol 2007;14(December (12)):1596-602.
17. Plested JS, Granoff DM. Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B. Clin Vaccine Immunol 2008;15(May (5)):799-804.
18. Granoff DM. Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease. Vaccine 2009;27(June (Suppl. 2)):B117-25.
19. Welsch JA, Moe GR, Rossi R, Adu-Bobie J, Rappuoli R, Granoff DM. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complementmediated bactericidal activity. J Infect Dis 2003;188(December (11)): 1730-40.
20. Hibberd ML, Sumiya M, Summerfield JA, Booy R, Levin M. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group. Lancet 1999;353(March (9158)):1049-53.
21. Jack DL, Lee ME, Turner MW, Klein NJ, Read RC. Mannose-binding lectin enhances phagocytosis and killing of Neisseria meningitidis by human macrophages. J Leukoc Biol 2005;77(March (3)):328-36.
22. Auckland C, Gray S, Borrow R, Andrews N, Goldblatt D, Ramsay M, et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis 2006;194(December (12)):1745-52.
23. Welsch JA, Ram S, Factor H. Neisserial pathogenesis. Vaccine 2008;26(December (Suppl. 8)):I40-5.
24. Shaughnessy J, Lewis LA, Jarva H, Ram S. Functional comparison of the binding of factor H short consensus repeat 6 (SCR 6) to factor H binding protein from Neisseria meningitidis and the binding of factor H SCR 18 to 20 to Neisseria gonorrhoeae porin. Infect Immun 2009;77(May (5)):2094-103.
25. Granoff DM, Welsch JA, Ram S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun 2009;77(February (2)):764-9.
26. Lucas AH, Granoff DM. A major crossreactive idiotype associated with human antibodies to the Haemophilus influenzae b polysaccharide. Expression in relation to age and immunoglobulin G subclass. J Clin Invest 1990;85(April (4)):1158-66.
27. Lucas AH, Granoff DM. Functional differences in idiotypically defined IgG1 antipolysaccharide antibodies elicited by vaccination with Haemophilus influenzae type B polysaccharide-protein conjugates. J Immunol 1995;154(April (8)):4195-202.
28. Lucas AH, Azmi FH, Mink CM, Granoff DM. Age-dependent V region expression in the human antibody response to the Haemophilus influenzae type b polysaccharide. J Immunol 1993;150(March (5)):2056-61.
29. Granoff DM, Holmes SJ, Osterholm MT, McHugh JE, Lucas AH, Anderson EL, et al. Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines. J Infect Dis 1993;168(September (3)):663-71.